Prevymis® (letermovir) – Updated label

- On August 2, 2023, the FDA approved an update to the drug label for Merck's Prevymis (letermovir), to allow for extension of the dosing regimen from 100 to 200 days post-transplant for the prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV seropositive recipients (R+) of an allogeneic hematopoietic stem cell transplant (HSCT) who are at risk for late CMV infection and disease.
    - Previously, Prevymis was approved through day 100 post-HSCT in this patient population.
    - Prevymis is initiated between day 0 and day 28 post-HSCT (before or after engraftment).
- Prevymis is also approved for the prophylaxis of CMV disease in adult kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]).
    - For this indication, Prevymis is initiated between day 0 and day 7 post-transplant and continued through day 200 posttransplant.
- The recommended dosage of Prevymis is 480 mg administered orally or intravenously once daily.